Lancet: results of phase III clinical trials of the Russian vaccine Sputnik V

The respected scientific journal Lancet has published the results of Phase III clinical trials of the Russian vaccine against Sputnik V coronavirus, reports BBC

Lancet: results of phase III clinical trials of the Russian vaccine Sputnik V

The Russian Sputnik V vaccine is 91.6% effective against coronavirus, according to preliminary results of the study, which was conducted on 20,000 people.

“As part of the secondary analysis, the authors distinguished between a study on the effectiveness of the vaccine against moderate or severe Covid-19. Twenty-one days after the first dose, there were no cases of moderate or severe disease in the vaccinated group”, –  the study results said.

Most side-effects were flu symptoms: headache, fever up to 38 degrees, pain at the injection site, feeling of weakness.
Also taking part in the study were 2,144 people over the age of 60. In this group, the vaccine was 91.8% effective. The side effects included all the same flu symptoms and a local reaction to the shot.

The authors of the article emphasise that “adenovirus vector vaccines have been used before, and their safety has been confirmed by several clinical trials”. It was on this platform that the Russian coronavirus vaccine Sputnik V was developed.

Comments:

comments powered by HyperComments